126 related articles for article (PubMed ID: 21436127)
1. Oversulfated chondroitin sulfate and OSCS-contaminated heparin cause dose- and route-dependent hemodynamic effects in the rat.
Corbier A; Le Berre N; Rampe D; Meng H; Lorenz M; Vicat P; Potdevin S; Doubovetzky M
Toxicol Sci; 2011 Jun; 121(2):417-27. PubMed ID: 21436127
[TBL] [Abstract][Full Text] [Related]
2. Structure elucidation and biological activity of the oversulfated chondroitin sulfate contaminant in Baxter heparin.
McKee J; Bairstow S; Szabo C; Ray J; Wielgos T; Hu P; Chess E; Nordhaus M; Hai T; Campbell J; Donovan S; Viseux N; Riedel N; Cammack J; Johnson R
J Clin Pharmacol; 2010 Oct; 50(10):1159-70. PubMed ID: 20147614
[TBL] [Abstract][Full Text] [Related]
3. Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products.
Bairstow S; McKee J; Nordhaus M; Johnson R
Anal Biochem; 2009 May; 388(2):317-21. PubMed ID: 19289093
[TBL] [Abstract][Full Text] [Related]
4. Contaminated heparin associated with adverse clinical events and activation of the contact system.
Kishimoto TK; Viswanathan K; Ganguly T; Elankumaran S; Smith S; Pelzer K; Lansing JC; Sriranganathan N; Zhao G; Galcheva-Gargova Z; Al-Hakim A; Bailey GS; Fraser B; Roy S; Rogers-Cotrone T; Buhse L; Whary M; Fox J; Nasr M; Dal Pan GJ; Shriver Z; Langer RS; Venkataraman G; Austen KF; Woodcock J; Sasisekharan R
N Engl J Med; 2008 Jun; 358(23):2457-67. PubMed ID: 18434646
[TBL] [Abstract][Full Text] [Related]
5. [Anaphylactoid reactions associated with contaminated heparin from China].
Montpas N; Désormeaux A; Keire D; Adam A
Ann Pharm Fr; 2011 Sep; 69(5):258-64. PubMed ID: 21924126
[TBL] [Abstract][Full Text] [Related]
6. Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate.
Clark M; Hoppensteadt D; Walenga J; Myers L; Cunanan J; Jeske W; Adiguzel C; Iqbal O; Fareed J
Int Angiol; 2008 Oct; 27(5):370-6. PubMed ID: 18974698
[TBL] [Abstract][Full Text] [Related]
7. Interactions of oversulfated chondroitin sulfate (OSCS) from different sources with unfractionated heparin.
Gray A; Litinas E; Jeske W; Fareed J; Hoppensteadt D
Clin Appl Thromb Hemost; 2012; 18(2):166-73. PubMed ID: 22311630
[TBL] [Abstract][Full Text] [Related]
8. Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro.
Adam A; Montpas N; Keire D; Désormeaux A; Brown NJ; Marceau F; Westenberger B
Biomaterials; 2010 Aug; 31(22):5741-8. PubMed ID: 20427081
[TBL] [Abstract][Full Text] [Related]
9. Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin.
Viskov C; Bouley E; Hubert P; Martinez C; Herman F; Jeske W; Hoppensteadt D; Walenga JM; Fareed J
Clin Appl Thromb Hemost; 2009; 15(4):395-401. PubMed ID: 19617248
[TBL] [Abstract][Full Text] [Related]
10. Determination of oversulfated chondroitin sulfate and dermatan sulfate impurities in heparin by capillary electrophoresis.
Somsen GW; Tak YH; Toraño JS; Jongen PM; de Jong GJ
J Chromatogr A; 2009 May; 1216(18):4107-12. PubMed ID: 19272607
[TBL] [Abstract][Full Text] [Related]
11. The effect of increasing the sulfation level of chondroitin sulfate on anticoagulant specific activity and activation of the kinin system.
Hogwood J; Naggi A; Torri G; Page C; Rigsby P; Mulloy B; Gray E
PLoS One; 2018; 13(3):e0193482. PubMed ID: 29494632
[TBL] [Abstract][Full Text] [Related]
12. Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin.
Adiguzel C; Bansal V; Litinas E; Cunanan J; Iqbal O; Nelson K; Kannan M; Hoppensteadt D; Fareed J
Clin Appl Thromb Hemost; 2009; 15(2):145-51. PubMed ID: 19357103
[TBL] [Abstract][Full Text] [Related]
13. Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes.
Warkentin TE; Greinacher A
Expert Opin Drug Saf; 2009 Mar; 8(2):129-44. PubMed ID: 19309242
[TBL] [Abstract][Full Text] [Related]
14. Combining (1)H NMR spectroscopy and chemometrics to identify heparin samples that may possess dermatan sulfate (DS) impurities or oversulfated chondroitin sulfate (OSCS) contaminants.
Zang Q; Keire DA; Wood RD; Buhse LF; Moore CM; Nasr M; Al-Hakim A; Trehy ML; Welsh WJ
J Pharm Biomed Anal; 2011 Apr; 54(5):1020-9. PubMed ID: 21215547
[TBL] [Abstract][Full Text] [Related]
15. Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008.
McMahon AW; Pratt RG; Hammad TA; Kozlowski S; Zhou E; Lu S; Kulick CG; Mallick T; Dal Pan G
Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):921-33. PubMed ID: 20661880
[TBL] [Abstract][Full Text] [Related]
16. Contaminated heparin.
Kakkar AK; Bonnefoi M
N Engl J Med; 2008 Sep; 359(12):1292-3; author reply 1293. PubMed ID: 18810795
[No Abstract] [Full Text] [Related]
17. Oversulfated chondroitin sulfate interaction with heparin-binding proteins: new insights into adverse reactions from contaminated heparins.
Li B; Suwan J; Martin JG; Zhang F; Zhang Z; Hoppensteadt D; Clark M; Fareed J; Linhardt RJ
Biochem Pharmacol; 2009 Aug; 78(3):292-300. PubMed ID: 19389385
[TBL] [Abstract][Full Text] [Related]
18. Sensitive detection of oversulfated chondroitin sulfate in heparin sodium or crude heparin with a colorimetric microplate based assay.
Sommers CD; Mans DJ; Mecker LC; Keire DA
Anal Chem; 2011 May; 83(9):3422-30. PubMed ID: 21449571
[TBL] [Abstract][Full Text] [Related]
19. Heparin identification test and purity test for OSCS in heparin sodium and heparin calcium by weak anion-exchange high-performance liquid chromatography.
Hashii N; Kawasaki N; Itoh S; Qin Y; Fujita N; Hattori T; Miyata K; Bando A; Sekimoto Y; Hama T; Kashimura M; Tatsumi M; Mabuchi K; Namekawa H; Sakai T; Hirose M; Dobashi S; Shimahashi H; Koyama S; Herr SO; Kawai K; Yoden H; Yamaguchi T
Biologicals; 2010 Sep; 38(5):539-43. PubMed ID: 20452241
[TBL] [Abstract][Full Text] [Related]
20. Case study: contamination of heparin with oversulfated chondroitin sulfate.
Chess EK; Bairstow S; Donovan S; Havel K; Hu P; Johnson RJ; Lee S; McKee J; Miller R; Moore E; Nordhaus M; Ray J; Szabo C; Wielgos T
Handb Exp Pharmacol; 2012; (207):99-125. PubMed ID: 22566223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
